한글목차

2024년까지 전 세계 16개국에서 급성관상동맥증후군(ACS) 입원 환자가 780만 명 이상 발생할 것으로 예상됩니다. ACS 시장에서 유망한 혁신 개발에는 새로운 경구용 P2Y 퓨린수용체 12(P2Y12) 수용체 억제제가 포함되며, ACS 파이프라인에는 17개의 분자가 있습니다. 3종의 임상 3상 파이프라인과 4종의 임상 2상 파이프라인이 있습니다.

지난 10년간 ACS의 임상시험 기관 수는 미국이 723개로 가장 많았고, 중국이 550개 이상으로 그 뒤를 이었습니다. 지난 10년간 북미와 아시아태평양에서는 인수가 가장 일반적인 거래 형태였습니다. 유럽에서는 라이선스 계약이 주류를 이루었습니다.

이 보고서는 세계 급성관상동맥증후군 시장을 조사하여 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 시판약
• 작용기서별 개요
• 분자 유형별 개요
• 제품 프로파일과 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지 시간

제6장 파이프라인 약제 평가

• 중기에서 후기 단계 파이프라인 약제
• 개발 단계별 개요
• 작용기서별 개요
• 분자 유형별 개요
• 약제 고유의 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야와 적응증별 PTSR과 LoA

제7장 임상시험 평가

• 실적 개요
• 상별 개요
• 상황별 개요
• 진행중 및 계획중인 시험의 상별 개요
• 가상 컴포넌트 시험
• 지역의 시험 개요
• 지역별 단일국 및 다국간 시험
• 상별 스폰서 상위 20개사
• 상황별 스폰서 상위 20개사
• 엔드포인트 상황별 개요
• 인종과 민족별 개요
• 등록 데이터
• 임상시험 실시 시설 상위 20개국
• 세계의 상위 20개 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

• 주요 시장 진출 기업

제10장 향후 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Acute coronary syndrome therapeutics.

• In 2024, more than 7.8 million hospitalized incident cases of ACS are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for ACS.
• Promising innovator developments in the ACS market include newer oral P2Y purinoceptor 12 (P2Y12)-receptor inhibitors.
• There are 17 molecules in the pipeline for ACS. The Phase III pipeline consists of three drugs, followed by four drugs in Phase II.
• Over the past 10 years, the US has hosted the highest number of trial sites for ACS, at 723 trial sites, followed by China with more than 550 trial sites.
• During the past decade, acquisitions were the most common deal type in North America and in Asia-Pacific. In Europe, licensing agreements were the predominant deal type.

Scope

GlobalData's Acute coronary syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Acute coronary syndrome market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Acute coronary syndrome market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer